Attention deficit hyperactivity disorder pharmacogenetics: The dopamine transporter and D4 receptor

Pharmacogenomics

Volumn 13, Issue 4, 2012, Pages 365-368

  McGough, James J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

amphetamine; candidate genes; genetics; methylphenidate; treatment

Indexed keywords

AMPHETAMINE; DOPAMINE 4 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; CORPUS STRIATUM; DAT GENE; DOPAMINE UPTAKE; DRD4 GENE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG TOLERABILITY; GENE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; PHARMACOGENETICS; REVIEW; SLC6A3 GENE; UNSPECIFIED SIDE EFFECT; VARIABLE NUMBER OF TANDEM REPEAT;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOMARKERS, PHARMACOLOGICAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, DOPAMINE D4;

EID: 84857755456     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.5     Document Type: Review

References (20)

1. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003 and 2007. MMWR Morb. Mortal. Wkly Rep. 59, 1439-1443 (2010).
2. Kessler RC, Adler L, Barkley R et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am. J. Psychiatry 163, 716-723 (2006).
3. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr. Clin. North Am. 33, 159-180 (2010).
4. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M et al. ADHD: clinical practice guidelines for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128, 1007-1022 (2011).
5. Greenhill L, Abikoff H, Arnold LE et al. Medication treatment strategies in the MTA: relevance to clinicians and researchers. J. Am. Acad. Child Adolesc. Psychiatry 35, 1304-1313 (1996).
6. Thiruchelvam D, Charch A, Schachar RJ. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 40, 922-928 (2001).
7. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J. Am. Acad. Child Adolesc. Psychiatry 43, 559-567 (2004).
8. Owens EB, Hinshaw SP, Kraemer HC et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J. Consult. Clin. Psychol. 71, 540-552 (2003).
9. Lowe N, Barry E, Gill M, Hawi Z. An overview of the pharmacogenetics and molecular genetics of ADHD. Curr. Pharmacogenomics 4, 231-243 (2006).
10. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs 24, 99-117 (2010).
11. McGough JJ, McCracken JT, Loo SK et al. A candidate gene analysis of methylphenidate response in attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 48, 1155-1164 (2009).
12. Swanson JM, Flodman P, Kennedy J et al. Dopamine genes and ADHD. Neurosci. Biobehav. Res. 24, 21-25 (2000).
13. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6, 55 (2005).
14. Polanczyk G, Faraone SV, Bau CH et al. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetics studies from four different continents. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1419-1424 (2008).
15. Gruber R, Joober R, Grizenko N, Leventhal BL, Cook EH, Stein MA. Dopamine transporter genotype and stimulant side effect factors in youth diagnosed with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 19, 233-239 (2009).
16. Froehlich TE, Epstein JN, Nick TG et al. Pharmacogenetic predictors of methylphenidate dose-response in attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 50, 1129-1139 (2011).
17. Van Tol HH, Wu CM, Guan HC et al. Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992).
18. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
19. McGough JJ, McCracken JT, Swanson J et al. Pharmacogenetics of methylphenidate response in preschoolers with ADHD. J. Am. Acad. Child Adolesc. Psychiatry 45, 1314-1322 (2006).
20. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol. Psychiatry 57, 1367-1374 (2005).